Aβ imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease

Victor L. Villemagne; William E. Klunk; Chester A. Mathis; Christopher C. Rowe; David J. Brooks; Bradley T. Hyman; Milos D. Ikonomovic; Kenji Ishii; Clifford R. Jack; William J. Jagust; Keith A. Johnson; Robert A. Koeppe; Val J. Lowe; Colin L. Masters; Thomas J. Montine; John C. Morris; Agneta Nordberg; Ronald C. Petersen; Eric M. Reiman; Dennis J. Selkoe; Reisa A. Sperling; Koen Van Laere; Michael W. Weiner; Alexander Drzezga

doi:10.1007/s00259-011-2045-0

Aβ imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease

Victor L. Villemagne, William E. Klunk, Chester A. Mathis, Christopher C. Rowe, David J. Brooks, Bradley T. Hyman, Milos D. Ikonomovic, Kenji Ishii, Clifford R. Jack, William J. Jagust, Keith A. Johnson, Robert A. Koeppe, Val J. Lowe, Colin L. Masters, Thomas J. Montine, John C. Morris, Agneta Nordberg, Ronald C. Petersen, Eric M. Reiman, Dennis J. SelkoeReisa A. Sperling, Koen Van Laere, Michael W. Weiner, Alexander Drzezga

Research output: Contribution to journal › Editorial › peer-review

40 Scopus citations

Original language	English (US)
Pages (from-to)	209-219
Number of pages	11
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	39
Issue number	2
DOIs	https://doi.org/10.1007/s00259-011-2045-0
State	Published - Feb 2012

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-011-2045-0

Cite this

Villemagne, V. L., Klunk, W. E., Mathis, C. A., Rowe, C. C., Brooks, D. J., Hyman, B. T., Ikonomovic, M. D., Ishii, K., Jack, C. R., Jagust, W. J., Johnson, K. A., Koeppe, R. A., Lowe, V. J., Masters, C. L., Montine, T. J., Morris, J. C., Nordberg, A., Petersen, R. C., Reiman, E. M., ... Drzezga, A. (2012). Aβ imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 39(2), 209-219. https://doi.org/10.1007/s00259-011-2045-0

Villemagne, VL, Klunk, WE, Mathis, CA, Rowe, CC, Brooks, DJ, Hyman, BT, Ikonomovic, MD, Ishii, K, Jack, CR, Jagust, WJ, Johnson, KA, Koeppe, RA, Lowe, VJ, Masters, CL, Montine, TJ, Morris, JC, Nordberg, A, Petersen, RC, Reiman, EM, Selkoe, DJ, Sperling, RA, Van Laere, K, Weiner, MW & Drzezga, A 2012, 'Aβ imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease', European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 2, pp. 209-219. https://doi.org/10.1007/s00259-011-2045-0

@article{83c223f75e454b23a5f54983c4742fc4,

title = "Aβ imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease",

author = "Villemagne, {Victor L.} and Klunk, {William E.} and Mathis, {Chester A.} and Rowe, {Christopher C.} and Brooks, {David J.} and Hyman, {Bradley T.} and Ikonomovic, {Milos D.} and Kenji Ishii and Jack, {Clifford R.} and Jagust, {William J.} and Johnson, {Keith A.} and Koeppe, {Robert A.} and Lowe, {Val J.} and Masters, {Colin L.} and Montine, {Thomas J.} and Morris, {John C.} and Agneta Nordberg and Petersen, {Ronald C.} and Reiman, {Eric M.} and Selkoe, {Dennis J.} and Sperling, {Reisa A.} and {Van Laere}, Koen and Weiner, {Michael W.} and Alexander Drzezga",

note = "Funding Information: Conflicts of interest This response represents a consensus opinion of all coauthors, is meant to apply to all current amyloid PET tracers equally, and is not meant to favor any one particular tracer over any other. Two coauthors (WEK and CAM) have a conflict of interest based on being coinventors of an amyloid imaging tracer licensed by GE Healthcare, several coauthors (AD, MDI, KI, WJJ, KAJ, WEK, VJL, CLM, CAM, AN, RCP, EMR, CCR, RAS, KVL, VLV, and MWW) have been paid consultants to or received research grant support from one or more of the companies developing commercial amyloid imaging tracers (AstraZeneca, Bayer Schering, GE Healthcare Merck and/or Avid/Lilly) and one coauthor (DJB) holds a part-time position as a Senior Neurologist with GE Healthcare. Six coauthors have no conflicts of interest relative to amyloid PET tracers (BTH, CRJ, RAK, TJM, JCM, DJS).",

year = "2012",

month = feb,

doi = "10.1007/s00259-011-2045-0",

language = "English (US)",

volume = "39",

pages = "209--219",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Aβ imaging

T2 - Feasible, pertinent, and vital to progress in Alzheimer's disease

AU - Villemagne, Victor L.

AU - Klunk, William E.

AU - Mathis, Chester A.

AU - Rowe, Christopher C.

AU - Brooks, David J.

AU - Hyman, Bradley T.

AU - Ikonomovic, Milos D.

AU - Ishii, Kenji

AU - Jack, Clifford R.

AU - Jagust, William J.

AU - Johnson, Keith A.

AU - Koeppe, Robert A.

AU - Lowe, Val J.

AU - Masters, Colin L.

AU - Montine, Thomas J.

AU - Morris, John C.

AU - Nordberg, Agneta

AU - Petersen, Ronald C.

AU - Reiman, Eric M.

AU - Selkoe, Dennis J.

AU - Sperling, Reisa A.

AU - Van Laere, Koen

AU - Weiner, Michael W.

AU - Drzezga, Alexander

N1 - Funding Information: Conflicts of interest This response represents a consensus opinion of all coauthors, is meant to apply to all current amyloid PET tracers equally, and is not meant to favor any one particular tracer over any other. Two coauthors (WEK and CAM) have a conflict of interest based on being coinventors of an amyloid imaging tracer licensed by GE Healthcare, several coauthors (AD, MDI, KI, WJJ, KAJ, WEK, VJL, CLM, CAM, AN, RCP, EMR, CCR, RAS, KVL, VLV, and MWW) have been paid consultants to or received research grant support from one or more of the companies developing commercial amyloid imaging tracers (AstraZeneca, Bayer Schering, GE Healthcare Merck and/or Avid/Lilly) and one coauthor (DJB) holds a part-time position as a Senior Neurologist with GE Healthcare. Six coauthors have no conflicts of interest relative to amyloid PET tracers (BTH, CRJ, RAK, TJM, JCM, DJS).

PY - 2012/2

Y1 - 2012/2

UR - http://www.scopus.com/inward/record.url?scp=84859632987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859632987&partnerID=8YFLogxK

U2 - 10.1007/s00259-011-2045-0

DO - 10.1007/s00259-011-2045-0

M3 - Editorial

C2 - 22218879

AN - SCOPUS:84859632987

SN - 1619-7070

VL - 39

SP - 209

EP - 219

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 2

ER -

Aβ imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this